Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Eisai Inc. and Exelixis, Inc.
Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell Carcinoma
The landscape of renal cell carcinoma (RCC) management has changed dramatically in recent years with the approval of new agents. The availability of these agents, along with data updates on their efficacy and safety, has complicated RCC treatment planning in terms of therapeutic selection and sequencing, toxicity management, and dose/schedule optimization. Additionally, positive results from studies of novel single-agent and combination therapies, biomarkers, and approved agents in new lines of therapy suggest more changes are on the horizon in RCC management. To help clinicians in their day-to-day practices, this case-based satellite symposium will broach a variety of clinical scenarios at key junctures in care, with the understanding that real-world scenarios cannot always be bucketed neatly into simple “lines of therapy.” The format of this activity will provide the audience with an opportunity to interact with the expert faculty panel and to reflect on how they arrive at the decisions they make, how their decisions compare with those of the faculty, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision making at key decision points along the RCC treatment continuum.
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.
Upon completion of this activity, participants will be able to:
- Substantiate their treatment decisions in the management of advanced RCC at key decision points along the disease continuum based on the most relevant clinical trial evidence
- Integrate knowledge of single-agent and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs switching decisions in the care of patients with advanced RCC
- Manage treatment-related toxicities and practically apply knowledge of adverse events as a component of monitoring and therapeutic decision making in RCC treatment settings
- Assess recent clinical trial results, key ongoing trials that are highly anticipated in the field, and how emerging strategies may further impact the RCC treatment landscape
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.